Page 118 - 《中国药科大学学报》2025年第4期

514 学报 Journal of China Pharmaceutical University 2025, 56(4): 507 − 514 第 56 卷

3073. [49] Cui S, Pan XJ, Ge CL, et al. Silybin alleviates hepatic lipid ac-
[36] Zhu XP, Bian H, Wang L, et al. Berberine attenuates nonalco- cumulation in methionine-choline deficient diet-induced nonal-
holic hepatic steatosis through the AMPK-SREBP-1c-SCD1 coholic fatty liver disease in mice via peroxisome proliferator-
pathway[J]. Free Radic Biol Med, 2019, 141: 192-204. activated receptor α[J]. Chin J Nat Med, 2021, 19(6): 401-411.
[37] Lu YZ, Zhang C, Song YY, et al. Gallic acid impairs fructose- [50] Gong XB, Li TJ, Wan RZ, et al. Cordycepin attenuates high-fat
driven de novo lipogenesis and ameliorates hepatic steatosis via diet-induced non-alcoholic fatty liver disease via down-regula-
AMPK-dependent suppression of SREBP-1/ACC/FASN cas- tion of lipid metabolism and inflammatory responses[J]. Int Im-
cade[J]. Eur J Pharmacol, 2023, 940: 175457. munopharmacol, 2021, 91: 107173.
[38] Yang SM, Duan ZG, Zhang S, et al. Ginsenoside Rh4 improves [51] Liu XY, Hu M, Ye C, et al. Isosilybin regulates lipogenesis and
hepatic lipid metabolism and inflammation in a model of fatty acid oxidation via the AMPK/SREBP-1c/PPARα
NAFLD by targeting the gut liver axis and modulating the FXR pathway[J]. Chem Biol Interact, 2022, 368: 110250.
signaling pathway[J]. Foods, 2023, 12(13): 2492. [52] Zhang JX, Zhang WX, Yang L, et al. Phytochemical Gallic acid
[39] Mu Q, Wang H, Tong L, et al. Betulinic acid improves nonalco-
alleviates nonalcoholic fatty liver disease via AMPK-ACC-
holic fatty liver disease through YY1/FAS signaling pathway[J].
PPARa axis through dual regulation of lipid metabolism and mi-
FASEB J, 2020, 34(9): 13033-13048.
tochondrial function[J]. Phytomedicine, 2023, 109: 154589.
[40] Pengnet S, Sumarithum P, Phongnu N, et al. Naringin attenu-
[53] Hai Y, Zuo L, Wang M, et al. Icariin alleviates nonalcoholic fat-
ates fructose-induced NAFLD progression in rats through re-
ty liver disease in polycystic ovary syndrome by improving liv-
ducing endogenous triglyceride synthesis and activating the
er fatty acid oxidation and inhibiting lipid accumulation[J].
Nrf2/HO-1 pathway[J]. Front Pharmacol, 2022, 13: 1049818.
Molecules, 2023, 28(2): 517.
[41] Zhang C, Hu JJ, Sheng L, et al. Ellagic acid ameliorates AKT-
[54] Huang YJ, Lang HD, Chen K, et al. Resveratrol protects against
driven hepatic steatosis in mice by suppressing de novo lipogen-
nonalcoholic fatty liver disease by improving lipid metabolism
esis via the AKT/SREBP-1/FASN pathway[J]. Food Funct,
and redox homeostasis via the PPARα pathway[J]. Appl Physi-
2019, 10(6): 3410-3420.
ol Nutr Metab, 2020, 45(3): 227-239.
[42] Li N, Yin L, Shang JM, et al. Kaempferol attenuates nonalco-
[55] Li X, Ge JD, Li YJ, et al. Integrative lipidomic and transcrip-
holic fatty liver disease in type 2 diabetic mice via the
tomic study unravels the therapeutic effects of saikosaponins A
Sirt1/AMPK signaling pathway[J]. Biomed Pharmacother,
and D on non-alcoholic fatty liver disease[J]. Acta Pharm Sin B,
2023, 165: 115113.
2021, 11(11): 3527-3541.
[43] Kim SJ, Hyun J. Altered lipid metabolism as a predisposing fac-
[56] Li Q, Tan JX, He Y, et al. Atractylenolide III ameliorates non-
tor for liver metastasis in MASLD[J]. Mol Cells, 2024, 47(2):
alcoholic fatty liver disease by activating hepatic adiponectin re-
100010.
ceptor 1-mediated AMPK pathway[J]. Int J Biol Sci, 2022,
[44] Yan CX, Zhang YR, Zhang XX, et al. Curcumin regulates en-
18(4): 1594-1611.
dogenous and exogenous metabolism via Nrf2-FXR-LXR path-
[57] Heeren J, Scheja L. Metabolic-associated fatty liver disease and
way in NAFLD mice[J]. Biomed Pharmacother, 2018, 105:
lipoprotein metabolism[J]. Mol Metab, 2021, 50: 101238.
274-281.
[58] Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on
[45] Shen BY, Wang YL, Cheng JQ, et al. Pterostilbene alleviated
the development and progression of non-alcoholic fatty liver
NAFLD via AMPK/mTOR signaling pathways and autophagy
disease[J]. J Hepatol, 2023, 78(5): 1048-1062.
by promoting Nrf2[J]. Phytomedicine, 2023, 109: 154561.
[59] Zhou JX, Zhang NH, Aldhahrani A, et al. Puerarin ameliorates
[46] Fan CW, Ling-Hu AL, Sun DL, et al. Nobiletin ameliorates
nonalcoholic fatty liver in rats by regulating hepatic lipid accu-
hepatic lipid deposition, oxidative stress, and inflammation by
mechanisms that involve the Nrf2/NF-κB axis in nonalcoholic mulation, oxidative stress, and inflammation[J]. Front Immunol,
fatty liver disease[J]. J Agric Food Chem, 2023, 71(50): 20105- 2022, 13: 956688.
20117. [60] Liu YY, Xu W, Zhai T, et al. Silibinin ameliorates hepatic lipid
[47] Kim SH, Yun C, Kwon D, et al. Effect of isoquercitrin on free accumulation and oxidative stress in mice with non-alcoholic
fatty acid-induced lipid accumulation in HepG2 cells[J]. steatohepatitis by regulating CFLAR-JNK pathway[J]. Acta
Molecules, 2023, 28(3): 1476. Pharm Sin B, 2019, 9(4): 745-757.
[48] Gao Q, Jia YZ, Yang GS, et al. PPARα-deficient ob/ob obese [61] Chen P, Li YS, Xiao L. Berberine ameliorates nonalcoholic fat-
mice become more obese and manifest severe hepatic steatosis ty liver disease by decreasing the liver lipid content via revers-
due to decreased fatty acid oxidation[J]. Am J Pathol, 2015, ing the abnormal expression of MTTP and LDLR[J]. Exp Ther
185(5): 1396-1408. Med, 2021, 22(4): 1109.